Navigation Links
Study Results Reveal Oral Growth Hormone Boosting Supplement May Be Capable of Producing the Same Benefits as Synthetic Growth Hormone Injections
Date:11/21/2013

NEW YORK, Nov. 21, 2013 /PRNewswire/ -- While human growth hormone (hGH) therapy has become a staple among the rich and famous thanks to its notoriety for purportedly being able to reduce wrinkles, tighten saggy skin, decrease body fat, increase lean muscle mass, boost energy, rev up sex drive, and make people look and feel decades — not years, but DECADES — younger, there has been a marked lack of clinical studies exploring these benefits. That's why a recent study on an oral growth hormone booster's effects on endurance garnered so much attention among experts attending the prestigious Obesity Week Conference held recently in Atlanta, Georgia.

The study revolved around SeroVital®, an hGH secretagogue that's been causing quite a stir at scientific conferences around the world ever since a group of some of the most renowned researchers in the world revealed that it was capable of increasing mean, serum (blood) growth hormone levels by 682%. This was headline news, because up until this point most felt the best way to increase hGH levels was through expensive prescription injections (costs can run as high as $1500 per month). In addition to their high cost, these synthetic hGH injections are extremely controversial, because some experts fear that introducing synthetic hGH into the body may upset the natural production of hGH.

"That's what makes SeroVital so different," says Dr. Amy Heaton, PhD, Director of Scientific Affairs for SanMedica International™, SeroVital's distributor. "Rather than introducing synthetic hGH into the body via injections, SeroVital increases the body's own, endogenous levels of human growth hormone by promoting pituitary health, the gland that manufactures hGH. SeroVital not only provides a more affordable way for people to raise their hGH levels, but does so in a clinically validated way that allows users to achieve this naturally and without the risks associated with injections."

And now SeroVital is making news again with the release of a study analyzing its effects on endurance. The results of this study showed that after two weeks of daily supplementation with this patented hGH secretagogue, not only was subjects' VO2max (the established measure of endurance) significantly increased, but numeric increases in both resting metabolic rate and estimated daily calorie expenditure were also seen.

"Increased measures of endurance are a well-established outcome of synthetic recombinant human growth hormone (rhGH) injections in adults," explains Dr. Heaton. "But our research on the SeroVital compound is so exciting because it's the first study of its kind to show that an oral growth hormone secretagogue may be capable of producing an expected benefit the same as that of synthetic hGH injections. And while the present study was not sufficiently powered to detect a significant change in mean resting metabolic rate and estimated daily calorie expenditure, these parameters showed increased values over baseline following the treatment period, evidencing the potential of the supplement to impart long-term fat burning effects."

The promise this research holds — especially because it doesn't require the administration of controversial synthetic hGH injections — could lead to an increased understanding of the ability of youthful growth hormone levels to impact excess body weight and fat mass, which is quickly becoming a major global health hazard. Dr. Heaton adds, "Further research in this area may provide insight to potential effects on body composition and weight regulation by the amino acid based hGH secretagogue. A larger multi-center study is being planned."

For more information about Obesity Week, visit www.ObesityWeek.com. To get the full details on SeroVital, visit www.SeroVital.com. You can purchase SeroVital directly from SanMedica International by calling 1-800-285-5192 or www.SeroVital.com. Use the promo code SERO43 at checkout and shipping is free.*

*Free standard shipping in the continental U.S. only.


'/>"/>
SOURCE SeroVital
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Irvine Center for Clinical Research Announces Open Enrollment for New Low Testosterone Study
2. Chicago Man Breathes Again Thanks to Northwestern Medicine Study
3. Phase IIb Study of Vanoxerine Shows Strong Safety and Statistically Significant Efficacy Signals for Treatment of Atrial Fibrillation
4. Zafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 2013
5. Epizymes EPZ-5676 DOT1L Inhibitor Demonstrates Encouraging Initial Findings in an Ongoing Phase 1 Dose Escalation Study
6. American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillions OVA1 Test in Presurgical Detection of Early-Stage Ovarian Cancer
7. American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillions Ovarian Cancer Test, OVA1
8. ChanRx to Present Results of Phase IIb Study in Atrial Fibrillation at the 2013 American Heart Association Scientific Sessions
9. Isis Pharmaceuticals Earns $1.5M from the Advancement of the Phase 2 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy
10. Certifications, Presentation of Study Results and Earnings Releases - Research Report on Agilent, Mindray, Bard, Tornier, and Life Technologies
11. Revalesio Initiates Phase IIa Study of RNS60 in Multiple Sclerosis at University Hospital Zurich
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 2017 Research and Markets has announced ... Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive ... offering. ... market was valued at US$ 7,167.6 Mn in 2015, and ... at a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/20/2017)... , April 20, 2017 Research and ... Pharmaceutical Contract Manufacturing Services Market Analysis By Service (Manufacturing, Research), ... Forecasts, 2014 - 2025" report to their offering. ... The Latin American pharmaceutical ... billion by 2025 Low drug registration cost in ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
Breaking Medicine Technology:
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Christie ... today announced an alliance with B. Braun Medical Inc. , a leader in ... in patient care with as many as 90 percent of hospital patients receiving a ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... On the heels of Thinksport’s award-winning sunscreen they’ve used the same scientific approach ... works! , Countless deodorants flood the aisles that contain harmful chemicals that should ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... Goodcents Deli ... open in the Lincoln, Neb. area this year. , The first new location ... The second location will open at 84th and Northern Lights Drive this fall. And ...
(Date:4/26/2017)... ... 26, 2017 , ... Jump Technologies, Inc., an innovative software ... completed a round of funding to accelerate its growth strategies. The $3.5 million ... is a growth equity firm focused on investments in healthcare and technology companies. ...
(Date:4/26/2017)... , ... April 26, 2017 , ... ... that describes the adoption of e-prescribing as measured in Part D Medicare data. ... deliver prescriptions to pharmacies, either using e-prescribing, faxes or paper. The PaPR ...
Breaking Medicine News(10 mins):